Parallel Trade in Belgium: Rebuffing the Critics
Stakeholders from the Belgian parallel trade industry outline how their activities are helping to solve medicine shortages in Europe and ensure patients have access to the medicines they need. They…
The Research Institute of Molecular Pathology (IMP) is a leading basic research institute. Its 15 research groups with scientists from 40 countries address fundamental questions in molecular biology. Funded primarily by Boehringer Ingelheim and with unconstrained academic freedom, the IMP is the ideal environment for curiosity-driven biomedical research. As part of the Vienna BioCenter (VBC), the IMP is embedded in one of Europe’s biggest life science hubs with 1600 employees.
Contact
Campus-Vienna-Biocenter 1A-1030 Vienna, Austria
Tel +43 (0) 1 79730 3609
Website: http://www.viennabiocenter.org/ https://www.imp.ac.at/
Email: office@viennabiocenter.org
Stakeholders from the Belgian parallel trade industry outline how their activities are helping to solve medicine shortages in Europe and ensure patients have access to the medicines they need. They…
Tanguy Schmitz, president of the Belgian Association of Parallel Importers & Exporters (BAPIE) outlines some of the recent work that the parallel distribution industry to ensure the supply of medicines…
Filip Van de Vliet and Gérard Lefèbvre of Alter Pharma Group discuss the value that parallel importing is bringing to Belgian patients and the evolving relationship between parallel importers and…
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their…
Orifarm is the largest supplier of parallel imported medicines in the EU and a fast-growing supplier of generic pharmaceuticals in the Nordic countries. Christian Vallentin, country manager of Orifarm Sweden,…
Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of…
Tomasz Dzitko, founder and CEO of Delfarma, Poland’s leading parallel importer, gives an overview of the sector in Poland and its impact on the healthcare ecosystem, as well as the…
Tatiane Galindo, executive director of Ortosintese, Brazil’s and Latin America’s leading implant company, provides insights into Ortosintese’s historical commitment to the highest quality standards and her ambitions to further bolstering…
Moez Lidinallah Mokaddem, ENA graduate and CEO of the Central Pharmacy of Tunisia (PCT), introduces the institution he works for and the central role it plays in the import of…
Harald Isemann, chairman of the Vienna Biocenter (VBC) – one of the leading life science hubs in Europe – and Managing Director of the Institute of Molecular Pathology (IMP), a…
See our Cookie Privacy Policy Here
